Stay updated with breaking news from Juan buela. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours SunRock Biopharma S.L. ("SunRock"), a biopharmaceutical company that is developing a portfolio ....
Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours LONDON and SANTIAGO DE COMPOSTELA, Spain, May 25, 2022: SunRock Biopharma S. ....
22 febbraio 2021 10:13 Fonte: Adnkronos #salute-e-benessere NANJING, China, Feb. 22, 2021 /PRNewswire/ On February 21, 2021, GenScript ProBio and SunRock Biopharma, a company focused on the development of antibody therapeutics targeting cancer, announced a collaboration spanning preclinical discovery to large scale GMP manufacturing for SunRock s CCR9 therapeutic antibody candidates. GenScript ProBio will provide SunRock Biopharma a one-stop-solution from antibody discovery, cell line development, process development to GMP drug substance and drug product manufacturing services. By leveraging complementary strengths and capabilities, the parties are committed to the R&D, manufacturing process development, NMPA, FDA & EMA IND filings of CCR9 therapeutic antibodies, towards rapid development of novel antibody therapeutics. ....
(1) NANJING, China, Feb. 22, 2021 /PRNewswire/ On February 21, 2021, GenScript ProBio and SunRock Biopharma, a company focused on the development of antibody therapeutics targeting cancer, announced a collaboration spanning preclinical discovery to large scale GMP manufacturing for SunRock s CCR9 therapeutic antibody candidates. GenScript ProBio will provide SunRock Biopharma a one-stop-solution from antibody discovery, cell line development, process development to GMP drug substance and drug product manufacturing services. By leveraging complementary strengths and capabilities, the parties are committed to the R&D, manufacturing process development, NMPA, FDA & EMA IND filings of CCR9 therapeutic antibodies, towards rapid development of novel antibody therapeutics. CCR9 is a novel therapeutic target expressed in highly aggressive cancer. It is associated with increased metastatic potential and tumor-chemoresistance. This program will enable new treatment formats wit ....